C10 - Decision-making and access to new medicines and technologies in health: Social, methodological and clinical challenges

Madrid 2

Organised by the FIP Social and Administrative Pharmacy Section in collaboration with FIP’s Industrial Pharmacy Section


Silvana Nair Leite, Federal University of Santa Catarina, Brazil


The Agenda 2030 established by the United Nations places among the goals for Sustainable Development the goal of “achieving universal health coverage, including access to safe, effective, quality and affordable medicines and essential vaccines for all” (United Nations, 2016). Nonetheless, technological advances in health – particularly new medicines – have substantially increased the costs of treatments. Health costs represent a global challenge for the sustainability of health systems, no longer limited to low- or middle-income countries. Both supranational organizations as well as countries have proposed guidelines and policies to implement the right to access to medicines, however, not always the demands of patients have been met. Strategies focused on health technologies assessment of new technologies have proved insufficient:

Strategies focused on health technologies assessment of new technologies have proved insufficient: first, uncertainty and distrust in decision-making processes of incorporation of new technologies by health systems agencies have questioned the incorporation of decisions; second, the prices of new technologies, always higher than the preview ones, have forfeited health systems and patients´ ability to pay. Control of prices, commercial agreements, patents issues, medicines clinical management, public-private institutions collaboration and other strategies have been developed in diverse countries to face the challenge of promote access to better treatments for patients. Pharmacists´ knowledge and practices have been recruited to lead policies decisions, appraisals management and patients’ evaluation in use of new technologies.


  1. Introduction: Ensure access to expensive medicines – A global challenge
    Silvana Nair Leite, Federal University of Santa Catarina, Brazil.
  2. Uncertainty in decision-making about the rationing of expensive medicines in England: A sociological view
    Michael Calnan, University of Kent, UK
  3. Access to high cost medicines in Europe and abroad: Challenges and new approaches
    Zaheer-ud-Din Babar, University of Huddersfield, UK
  4. Public-private partnership: Technological development, medicines production and costs reduction in Brazil
    Igor Linhares de Castro, BiocadBrazil Farmaceutica Ltda, Brazil
  5. Panel discussion and Q&A

Learning Objectives

At the end of this session, participants will be able to:

  1. Understand the complex social and professional environment of decision-making process of incorporation of a new technology
  2. Distinguish the methods, challenges and achievements diverse health systems have been experienced in promoting access to new medicines

Type of session: Knowledge-based